ALEMBIC LTD. - 506235 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2021, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice for claiming shares from Company's Unclaimed Suspense Account published by the Company in English language newspaper - Business Standard on Date: 5th January, 2022. We request you to kindly take the same on record.
Alembic gets USFDA nod for generic drug to treat bacterial infections
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Doxycycline Hyclate delayed-release tablets ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st January, 2022 till 48 hours after the declaration of the unaudited financial results for the quarter and nine months period ended 31st December, 2021. The date of the Board Meeting for considering the unaudited financial results for the quarter and nine months period ended 31st December, 2021, will be intimated in due course. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record.
Alembic gets USFDA nod for generic hypertension treatment drug
Alembic said it has so far received 15 product approvals this year ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record. ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the following registered shareholder(s) and/or legal heir(s) of the registered shareholder(s) on 1st December, 2021: We request you to kindly take the same on record.